KR20220113942A - 제조성 및 용출성이 우수한 소형 정제 - Google Patents

제조성 및 용출성이 우수한 소형 정제 Download PDF

Info

Publication number
KR20220113942A
KR20220113942A KR1020227019247A KR20227019247A KR20220113942A KR 20220113942 A KR20220113942 A KR 20220113942A KR 1020227019247 A KR1020227019247 A KR 1020227019247A KR 20227019247 A KR20227019247 A KR 20227019247A KR 20220113942 A KR20220113942 A KR 20220113942A
Authority
KR
South Korea
Prior art keywords
imeglimine
hydrochloride
less
tablet
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227019247A
Other languages
English (en)
Korean (ko)
Inventor
히로키 이카리
다카시 시미즈
요헤이 니시다
다이치 마츠모토
다쿠미 아사다
Original Assignee
스미토모 파마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미토모 파마 가부시키가이샤 filed Critical 스미토모 파마 가부시키가이샤
Publication of KR20220113942A publication Critical patent/KR20220113942A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Lasers (AREA)
KR1020227019247A 2019-12-13 2020-12-11 제조성 및 용출성이 우수한 소형 정제 Withdrawn KR20220113942A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019225718 2019-12-13
JPJP-P-2019-225718 2019-12-13
PCT/JP2020/046253 WO2021117861A1 (ja) 2019-12-13 2020-12-11 製造性及び溶出性に優れた小型錠剤

Publications (1)

Publication Number Publication Date
KR20220113942A true KR20220113942A (ko) 2022-08-17

Family

ID=76330003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019247A Withdrawn KR20220113942A (ko) 2019-12-13 2020-12-11 제조성 및 용출성이 우수한 소형 정제

Country Status (5)

Country Link
JP (2) JP7093473B2 (https=)
KR (1) KR20220113942A (https=)
CN (1) CN114945370A (https=)
TW (1) TW202135826A (https=)
WO (1) WO2021117861A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066326A1 (en) 2008-12-12 2010-06-17 Merck Patent Gmbh Combination of insulin with triazine derivatives and its use for treating diabetes
WO2011154497A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 2 diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
KR20190120430A (ko) * 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
JP5775223B2 (ja) * 2012-09-05 2015-09-09 テイカ製薬株式会社 口腔内速崩壊性錠剤用造粒物
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
JP6854162B2 (ja) * 2017-03-17 2021-04-07 ライオン株式会社 錠剤
CA3103324A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066326A1 (en) 2008-12-12 2010-06-17 Merck Patent Gmbh Combination of insulin with triazine derivatives and its use for treating diabetes
WO2011154497A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 2 diabetes

Also Published As

Publication number Publication date
JP2022123069A (ja) 2022-08-23
JPWO2021117861A1 (https=) 2021-06-17
TW202135826A (zh) 2021-10-01
WO2021117861A1 (ja) 2021-06-17
JP7671265B2 (ja) 2025-05-01
JP7093473B2 (ja) 2022-06-29
CN114945370A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
KR101290925B1 (ko) 코팅된 정제 제형 및 방법
KR100762847B1 (ko) 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
US20240091157A1 (en) Solid pharmaceutical compositions and processes for their production
CA2866377C (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
EP3313187B1 (en) Sustained release formulation and tablets prepared therefrom
EA029890B1 (ru) Фармацевтическая композиция и фармацевтическая композиция в пероральной дозированной лекарственной форме на основе ингибитора dpp iv
KR20100038386A (ko) 벤조아제핀을 포함하는 의약 고형 제제 및 그의 제조 방법
CA2733611A1 (en) Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
KR20170128323A (ko) 착색제를 함유하는 고형 제제
WO2014080384A1 (en) Pharmaceutical composition of linagliptin
KR20180125574A (ko) 용출성이 우수한 경구 제제
WO2013114389A1 (en) Process for preparing solid oral formulations comprising low dose of entecavir
CA2915432A1 (en) Disintegrant free composition of cinacalcet
TR2021009380A2 (tr) Amorf dapagliflozi̇n ve metformi̇n hi̇droklorür i̇çeren tablet formülasyonlari i̇çi̇n bi̇r proses
JP7671265B2 (ja) 製造性及び溶出性に優れた小型錠剤
WO2005123134A2 (en) A controlled release delivery system for metformin
WO2017029609A1 (en) Pharmaceutical composition of alogliptin and metformin
WO2013036213A1 (en) Dpp-iv inhibitor formulations
HK40074201A (en) Small-sized tablet having excellent producibility and elution properties
EP3335702A1 (en) Pharmaceutical compositions comprising omarigliptin
CA2009044A1 (en) An erosion-controlled release system for active agents and a process for its preparation
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
KR102262408B1 (ko) 덱스케토프로펜 및 트라마돌을 함유하는 약제학적 조성물
KR102065090B1 (ko) 레베티라세탐 또는 이의 약제학적으로 허용되는 염을 함유하는 서방성 제제 및 이의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203